Get started
Author

Bryan Qvick

Observed name: B. Qvick
Institution: Ipsen (Germany)
ORCID: 0000-0001-8759-7783
Observed ORCID: 0000-0001-8759-7783
OpenAlex ID: A5068740875
CaboPoint: Interim results from a phase 2 study of cabozantinib after checkpoint inhibitor (CPI) therapy in patients with advanced renal cell carcinoma (RCC).
2023 · Laurence Albiges, Thomas Powles, et al. · Journal of Clinical Oncology · 27
Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III
2016 · for the OPTIC III Study Group, Thorsten Bach, et al. · World Journal of Urology · 19
PDF
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma
2025 · Laurence Albiges, Thomas Powles, et al. · European Urology · 9
Retrospective German claims data study on initial treatment of bladder carcinoma (BCa) by transurethral bladder resection (TURB): a comparative analysis of costs using standard white light- (WL-) vs. blue light- (BL-) TURB
2021 · Tilman Todenhöfer, Moritz Maas, et al. · World Journal of Urology · 9
PDF
1693P CaboPoint: Final results from a phase II study of cabozantinib after checkpoint inhibitor (CPI) combinations in patients with advanced renal cell carcinoma (aRCC)
2024 · L. Albiges, T.B. Powles, et al. · Annals of Oncology · 7
Kosten-Effektivitäts-Analyse zur Verwendung der Blaulichtzystoskopie mit Hexylaminolevulinat bei der transurethralen Resektion der Harnblase
2018 · G. Gakis, B. Volkmer, et al. · Der Urologe · 5
CaboCombo: a prospective, phase IV study of first-line cabozantinib + nivolumab for advanced renal cell carcinoma
2023 · Philippe Barthélémy, Pascale Dutailly, et al. · Future Oncology · 3
A Prospective Non-interventional Real-World Study of cabozantinib in Pretreated Patients With Advanced Renal Cell Carcinoma Refractory to Vascular Endothelial Growth Factor-Targeted Therapy (CASSIOPE)
2024 · Michael Staehler, Umberto Basso, et al. · Clinical Genitourinary Cancer · 2
PDF
CaboCombo: A prospective international non-interventional study of first-line cabozantinib plus nivolumab for the treatment of patients with advanced renal cell carcinoma.
2023 · Philippe Barthelemy, Pascale Dutailly, et al. · Journal of Clinical Oncology · 1
PDF
SA40 European Multi-Country Real-World Effectiveness in Oncology Using Physician and Patient Survey Data: What Did We Learn?
2024 · J. Bedke, A. Houchard, et al. · Value in Health
P192 CaboCombo: interim analyses from an international real-world study assessing the use of cabozantinib plus nivolumab (CaboNivo) as first-line (1L) treatment for advanced Renal Cell Carcinoma (aRCC)
2024 · P. Barthélémy, P. Gimel, et al. · European Urology Open Science
CASSIOPE: A prospective noninterventional study of cabozantinib treatment following prior vascular endothelial growth factor (VEGF) -targeted therapy in patients with advanced renal cell carcinoma (aRCC).
2023 · Michael D. Staehler, Pierre Bigot, et al. · Journal of Clinical Oncology
Pcn502 Retrospective Gkv [gesetzliche Krankenversicherung (statutory Health Insurance)] Study on Initial Treatment of Bladder Carcinoma (bca) by Transurethral Bladder Resection (turb) - a Comparative Analysis of Costs and Urological Follow-up Therapies Using Standard White Light- (wl-) Vs. Blue Light- (bl-)turb
2019 · M. Maas, A. Stenzl, et al. · Value in Health
PDF
Works count: 13
Citation count: 82
H-index: 5
I10-index: 2
Year
Topic
Type